CURRENT LISTING OF CLAIMS

650 855 5322

. (previously amended) A compound according to formula I

wherein;

X¹ is selected from the group consisting of R⁵O, R⁵S(O)_n, R⁵CH₂O, R⁵CH₂O, R⁵CH₂S(O)_n, R⁵OCH₂, R⁵S(O)_nCH₂ and NR⁵R⁶;

RI and R2 are

- (i) each independently selected from the group consisting of hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₈ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ alkylsulfinyl, C₁₋₆ sulfonyl, C₁₋₆ haloalkoxy, C₁₋₆ haloalkylthio, halogen, amino, alkylamino, dialkylamino, aminoacyl, nitro and cyano; or,
- (ii) taken together are -CH=CII-CII=CH-, or
- (iii) taken together along with the carbons to which they are attached form a five- or sixmembered heteroaromatic or heterocyclic ring with a one or two heteroatoms independently selected from the group consisting of O, S and NH;
- R³ is selected from the group consisting of hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₈ cycloalkyl, C₁₋₆ alkylthio, C₁₋₆ haloalkylthio, halogen, amino, alkylamino, dialkylamino, aminoacyl, nitro and cyano;
- R⁴ is selected from the group consisting of hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₈ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ haloalkoxy, C₁₋₆ haloalkylthio, halogen, amino, alkylamino, dialkylamino, aminoacyl, nitro and cyano;
- R⁵ is selected from the group consisting of C₂₋₆ alkyl, haloalkyl, cycloalkyl, phenyl, naphthyl, pyridinyl, pyridine N-oxide, pyridine N-oxide, indole, indole N-oxide, quinoline, quinoline N-oxide, pyrimidinyl, pyrazinyl and pyrrolyl; wherein,
 - said alkyl and said cycloalkyl are optionally substituted with one or two substituents independently selected from the group consisting of alkyl, hydroxy, alkoxy, thiol, alkylthio, halogen, amino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, and dialkylamino; and,
 - said phenyl, said naphthyl, said pyridinyl, said pyridine N-oxide, said indole, said indole N-oxide, said quinoline, said quinoline N-oxide, said pyrimidinyl, said pyrazinyl and said

#143993 v3 2 R0169B-REG

pyrrolyl groups are optionally substituted with one to three substituents independently selected from the group consisting of C_{1-6} alkyl, C_{1-6} alkenyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} alkylsulfinyl, C_{1-6} sulfonyl, C_{1-6} haloalkoxy, C_{1-6} haloalkylthio, hydroxy, halogen, amino, C_{1-6} alkylamino, C_{1-6} dialkylamino, aminoacyl, acyl, C_{1-6} alkoxycarbonyl, carbamoyl, C_{1-6} N-alkylcarbamoyl, C_{1-6} N,N-dialkylcarbamoyl, nitro and cyano;

R⁶ is hydrogen, C₁₋₆ alkyl, or acyl;

R⁷ and R⁸ taken independently are selected from the group consisting of hydrogen, amino, C₁₋₆ alkylamino, C₁₋₆ dialkylamino, amino-C₁₋₃ alkyl, C₁₋₃ alkylamino-C₁₋₃ alkyl, C₁₋₃ dialkylamino-C₁₋₃ alkyl or C₁₋₆ alkyl optionally substituted with one or two substituents independently selected from the group consisting of hydroxy, alkoxy, thiol, alkylthio, C₁₋₆ alkylsulfinyl, C₁₋₆ sulfonyl and halogen, N-morpholinyl;

n is an integer from 0 to 2; or an acid addition salt thereof.

- 2. (previously amended) A compound according to claim 1 wherein
 - R⁵ is selected from the group consisting of C₂₋₆ alkyl, haloalkyl, cycloalkyl, phenyl, naphthyl, pyridinyl, pyrimidinyl, pyrazinyl and pyrrolyl; and,
 - said alkyl and said cycloalkyl are optionally substituted with one or two substituents independently selected from the group consisting of alkyl, hydroxy, alkoxy, thiol, alkylthio, halogen, amino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, and dialkylamino; and,
 - said phenyl, said naphthyl, said pyridinyl, said pyrimidinyl, said pyrazinyl and said pyrrolyl groups are optionally substituted with one to three substituents independently selected from the group consisting of C_{1.6} alkyl, C_{1.6} haloalkyl, C_{3.8} cycloalkyl, C_{1.6} alkoxy, C_{1.6} alkylthio, C_{1.6} alkylsulfinyl, C_{1.6} sulfonyl, C_{1.6} haloalkoxy, C_{1.6} haloalkylthio, halogen, alkylamino, dialkylamino, aminoacyl, cyano, and acyl.
 - 3. (original) A compound according to claim 2 wherein:

X¹ is OR⁵ or SR⁵;

R³ is hydrogen or fluoro;

R⁴ is selected from the group consisting of hydrogen, chloro, fluoro and methyl;

R⁵ is optionally substituted phenyl; and,

#143993 v3 R0169B-REG

- R⁷ and R⁸ are selected from the group consisting of hydrogen, amino, C₁₋₆ alkylamino, C₁₋₆ dialkylamino, amino-C₁₋₃ alkyl, C₁₋₃ alkylamino-C₁₋₃ alkyl and C₁₋₆ alkyl optionally substituted with hydroxy, alkoxy, thiol, alkylthio, halogen.
- 4. (original) A compound according to claim 3 wherein R¹ is methyl, ethyl, trifluoromethyl or halogen.
- 5. (original) A compound according to claim 4 wherein R⁵ is monosubstituted phenyl.
- 6. (original) A compound according to claim 4 wherein R⁵ is 2,5-disubstituted phenyl.
- 7. (original) A compound according to claim 4 wherein R⁵ is 3,5-disubstituted phenyl.
- 8. (original) A compound according to claim 4 wherein R⁵ is 2,4-disubstituted phenyl.
- 9. (original) A compound according to claim 4 wherein R⁵ is 2,6-disubstituted phenyl.
- 10. (original) A compound according to claim 2 wherein:

X1 is -OR5 or -SR5;

R¹ and R² are independently selected from the group consisting of hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₈ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ alkylsulfinyl, C₁₋₆ sulfonyl, C₁₋₆ haloalkylthio, halogen, amino, alkylamino, dialkylamino, aminoacyl, nitro and cyano; and

R³ is hydrogen or fluorine.

11. (original) A compound according to claim 10 wherein:

X1 is OR5;

R¹ is methyl, ethyl, trifluoromethyl or halogen;

R² and R⁴ are hydrogen, fluoro, chloro, methyl or ethyl:

R3 is hydrogen or fluoro;

R⁷ is hydrogen, methyl or ethyl; and,

R⁸ is selected from the group consisting of hydrogen, amino, C₁₋₆ alkylamino, C₁₋₆ dialkylamino, amino-C₁₋₃ alkyl, C₁₋₃ alkylamino-C₁₋₃ alkyl, C₁₋₃ dialkylamino-C₁₋₃ alkyl and C₁₋₆ alkyl optionally substituted with hydroxy, alkoxy, thiol, alkylthio, halogen.

#143993 v3

4

R0169B-REG

- 12. (original) A compound according to claim 11 wherein R⁵ is monosubstituted phenyl.
- 13. (original) A compound according to claim 12 wherein R⁵ is a monosubstituted phenyl and the substituent is selected from the group consisting of halogen, cyano, C₁₋₆ alkyl, C₁₋₆ alkenyl, C₃₋₈ cycloalkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio and C₁₋₆ haloalkoxy.
- 14. (original) A compound according to claim 13 wherein R¹ is selected from the group consisting of halogen, methyl, ethyl, R³ and R⁷ are hydrogen, R⁵ is a monosubstituted phenyl and the substituent is selected from the group consisting of halogen, cyano, C₁₋₆ alkyl and C₁₋₆ haloalkyl and R⁸ is selected from the group consisting of hydrogen, methyl and ethyl.
- 15. (original) A compound according to claim 11 wherein R⁵ is 2,5-disubstituted phenyl,
- 16. (original) A compound according to claim 15 wherein R⁵ is a 2,5-disubstituted phenyl and the substituents are independently selected from the group consisting of halogen, cyano, C₁₋₆ alkyl, C₁₋₆ alkenyl, C₃₋₈ cycloalkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio and C₁₋₆ haloalkoxy.
- 17. (original). A compound according to claim 16 wherein R¹ is selected from the group consisting of halogen, methyl, ethyl, R³ and R⁷ are hydrogen, R⁵ is a 2,5-disubstituted phenyl and the substituent is selected from the group consisting of halogen, cyano, C₁₋₆ alkyl and C₁₋₆ haloalkyl and R⁸ is selected from the group consisting of hydrogen, methyl and ethyl.
- 18. (original) A compound according to claim 11 wherein R⁵ is 3,5-disubstituted phenyl.
- 19. (original) A compound according to claim 18 wherein R⁵ is a 3,5-disubstituted phenyl and the substituents are independently selected from the group consisting of halogen, cyano, C₁₋₆ alkyl, C₁₋₆ alkenyl, C₃₋₈ cycloalkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio and C₁₋₆ haloalkoxy.
- 20. (original) A compound according to claim 19 wherein R¹ is selected from the group consisting of halogen, methyl, ethyl, R³ and R⁷ are hydrogen, R⁵ is a 3,5-disubstituted phenyl and the substituent is selected from the group consisting of halogen, eyano, C₁₋₆ alkyl and C₁₋₆ haloalkyl and R⁸ is selected from the group consisting of hydrogen, methyl and ethyl.

#143993 v3 5 R0169B-REG

21. (original) A compound according to claim 20 with formula Ia wherein:

R¹ is selected from the group consisting of fluoro, chloro, bromo and methyl;

R8 is selected from the group consisting of hydrogen, methyl and ethyl;

R⁹ is selected from the group consisting of C₁₋₆ alkyl, C₃₋₈ cycloalkyl, C₁₋₆ haloalkyl, halogen and cyano.

- 22. (original) A compound according to claim 11 wherein R⁵ is 2,4-disubstituted phenyl.
- 23. (original) A compound according to claim 22 wherein R⁵ is a 2,4-disubstituted phenyl and the substituents are independently selected from the group consisting of halogen, cyano, C₁₋₆ alkyl, C₁₋₆ alkenyl, C₃₋₈ cycloalkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio and C₁₋₆ haloalkoxy.
- 24. (original) A compound according to claim 23 wherein R¹ is selected from the group consisting of halogen, methyl, ethyl, R³ and R⁷ are hydrogen, R⁵ is a 2,4-disubstituted phenyl and the substituent is selected from the group consisting of halogen, cyano, C₁₋₆ alkyl and C₁₋₆ haloalkyl and R⁸ is selected from the group consisting of hydrogen, methyl and ethyl.
- 25. (original) A compound according to claim 11 wherein R³ is 2,6-disubstituted phenyl.
- 26. (original) A compound according to claim 25 wherein R⁵ is a 2,6-disubstituted phonyl and the substituents are independently selected from the group consisting of halogen, cyano, C₁₋₆ alkyl, C₁₋₆ alkenyl, C₃₋₈ cycloalkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio and C₁₋₆ haloalkoxy.
- 27. (original) A compound according to claim 26 wherein R¹ is selected from the group consisting of halogen, methyl, ethyl, R³ and R⁷ are hydrogen, R⁵ is a 2,6-disubstituted phenyl and the substituent is selected from the group consisting of halogen, cyano, C₁₋₆ alkyl and C₁₋₆ haloalkyl and R⁸ is selected from the group consisting of hydrogen, methyl and ethyl.

#143993 v3

- 28. (original) A compound according to claim 11 wherein R⁵ is a 2,3,5-trisubstituted phenyl.
- 29. (original) A compound according to claim 1 wherein:

X1 is OR5 or SR5:

R³ and R⁴ are selected from the group consisting of hydrogen, chloro, fluoro, and methyl;

R⁵ is optionally substituted pyridinyl, pyridine N-oxide, indole, indole N-oxide, quinoline, quinoline N-oxide, pyrimidinyl, pyrazinyl and pyrrolyl.

- 30. (original) A compound according to claim 1 wherein R¹ and R² along with the carbon atoms to which they are attached form a phenyl, dihydropyran, dihydrofuran or furan ring.
- 31. (original) A compound according to claim 30 wherein:

X1 is OR5 or SR5;

R³, and R⁷ are hydrogen;

R4 is hydrogen or fluoro;

R⁸ is hydrogen or methyl; and,

R⁵ is optionally substituted phenyl.

32. (previously amended) A method for treating an HIV-1 infection comprising administering to a host in need thereof a therapeutically effective amount of a compound of formula I

wherein.

X¹ is selected from the group consisting of R⁵O, R⁵S, R⁵CH₂O, R⁵CH₂O, R⁵CH₂S(O)_m, R⁵OCH₂, R⁵S(O)_mCH₂, NR⁵R⁶and R⁵C(=O);

R' and R² are

- (i) each independently selected from the group consisting of hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₈ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ alkylsulfinyl, C₁₋₆ sulfonyl, C₁₋₆ haloalkoxy, C₁₋₆ haloalkylthio, halogen, amino, alkylamino, dialkylamino, aminoacyl, nitro and cyano; or,
- (ii) taken together are -CH=CH-CH=CH-, or

#143993 v3

7

R0169B-REG

- (iii) taken together along with the carbons to which they are attached form a five- or sixmembered heteroaromatic or heterocyclic ring with a one or two heteroatoms independently selected from the group consisting of O, S and NH;
- R³ and R⁴ are each independently selected from the group consisting of hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₈ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ haloalkoxy, C₁₋₆ haloalkylthio, halogen, amino, alkylamino, dialkylamino, aminoacyl, nitro and cyano;
- R⁵ is selected from the group consisting of alkyl, haloalkyl, cycloalkyl, phenyl, naphthyl, pyridinyl, pyrimidinyl, pyrazinyl and pyrrolyl; wherein,
 - said alkyl and said cycloalkyl are optionally substituted with one or two substituents independently selected from the group consisting of alkyl, hydroxy, alkoxy, thiol, alkylthio, halogen, amino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, and dialkylamino; and,
 - said phenyl, said naphthyl, said pyridinyl, said pyrimidinyl, said pyrazinyl and said pyrrolyl groups are optionally substituted with one to three substituents independently selected from the group consisting of hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₈ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ alkylsulfinyl, C₁₋₆ sulfonyl, C₁₋₆ haloalkoxy, C₁₋₆ haloalkylthio, hydroxy, halogen, amino, alkylamino, dialkylamino, aminoacyl, acyl, alkoxycarbonyl, carbamoyl, N-alkylcarbamoyl, N,N-dialkylcarbamoyl, nitro and cyano;

R⁶ is hydrogen, C₁₋₆ alkyl, or acyl;

R⁷ and R⁸ taken independently are selected from the group consisting of hydrogen, , amino, C₁₋₅ alkylamino, C₁₋₆ dialkylamino, amino-C₁₋₃ alkyl, C₁₋₃ alkylamino-C₁₋₃ alkyl, C₁₋₃ dialkylamino-C₁₋₃ alkyl or C₁₋₆ alkyl optionally substituted with one or two substituents independently selected from the group consisting of hydroxy, alkoxy, thiol, alkylthio, C₁₋₆ alkylsulfinyl, C₁₋₆ sulfonyl and halogen, N-morpholinyl;

n is an integer from 0 to 2; or an acid addition salt thereof.

33. (original) A method according to claim 32 wherein:

X1 is OR5;

R¹ is methyl, ethyl, trifluoromethyl or halogen;

R² and R⁴ are independently hydrogen, fluoro, chloro, methyl or ethyl;

R³ is hydrogen or fluoro; and,

R⁵ is optionally substituted phenyl;

#143993 v3 8 R0169B-REG

R⁷ is hydrogen, methyl or ethyl.

34. (original) A method according to claim 33 comprising administering a compound of formula Ia wherein

$$\begin{array}{c|c} R^2 & & \\ & & \\ \hline \\ CN & & \\ \hline \\ CN & & \\ \end{array}$$

R¹ is selected from the group consisting of fluoro, chloro, bromo and methyl;

R⁸ is selected from the group consisting of hydrogen, methyl and ethyl;

R⁹ is selected from the group consisting of alkyl, cycloalkyl, haloalkyl, halogen and cyano.

- 35. (previously amended) A method for treating an HIV-1 infection according to claim 32 further comprising co-administering at least one compound selected from the group consisting of HIV protease inhibitors, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, CCR5 inhibitors and viral fusion inhibitors.
- 36. (original) A method according to claim 35 wherein the reverse transcriptase inhibitor is selected from the group consisting of zidovudine, lamivudine, didanosine, zalcitabine, stavudine, rescriptor, sustiva and viramune, efavirenz, nevirapine or delavirdine and/or the protease inhibitor is selected from the group consisting of saquinavir, ritonavir, nelfinavir, indinavir, amprenavir, lopinavir.
- 37. (currently amended) A method for inhibiting a HIV-1 reverse transcriptase comprising administering a compound according to claim 1 [[32]].
- 38. (currently amended) A method according to claim 37 wherein the host is infected with a strain of-HIV-1 expressing a reverse transcriptase with contains at least one mutation compared to wild type virus.
- 39. (previously amended) A method according to claim 32 wherein said strain of HIV-1 exhibits reduced susceptibility to of a virapine or delayirdine.
- 40. (currently amended) A pharmaceutical composition comprising a therapeutically effective quantity of a compound of formula I

#143993 v3 9 R0169B-REG

wherein:

X¹ is selected from the group consisting of R⁵O, R⁵S(O)_n, R⁵CH₂O, R⁵CH₂O, R⁵CH₂S(O)_m, R⁵OCH₂, R⁵S(O)_nCH₂ and NR⁵R⁶;

R1 and R2 are

- (i) each independently selected from the group consisting of hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₈ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ alkylsulfinyl, C₁₋₆ sulfonyl, C₁₋₆ haloalkoxy, C₁₋₆ haloalkylthio, halogen, amino, alkylamino, dialkylamino, aminoacyl, nitro and cyano; or,
- (ii) taken together are -CH=CH-CH=CH-, or
- (iii) taken together along with the carbons to which they are attached form a five- or six-membered heteroaromatic or heterocyclic ring with a one or two heteroatoms independently selected from the group consisting of O, S and NH;
- R³ is selected from the group consisting of hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₈ cycloalkyl, C₁₋₆ alkylthio, C₁₋₆ haloalkylthio, halogen, amino, alkylamino, dialkylamino, aminoacyl, nitro and cyano;
- R⁴ is selected from the group consisting of hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₈ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, C₁₋₆ haloalkylthio, halogen, amino, alkylamino, dialkylamino, aminoacyl, nitro and cyano;
- R⁵ is selected from the group consisting of alkyl, haloalkyl, cycloalkyl, phenyl, naphthyl, pyridinyl, pyrimidinyl, pyrazinyl and pyrrolyl; wherein,
 - said alkyl and said cycloalkyl are optionally substituted with one or two substituents independently selected from the group consisting of alkyl, hydroxy, alkoxy, thiol, alkylthio, halogen, amino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, and dialkylamino; and,
 - said phenyl, said naphthyl, said pyridinyl, said pyrimidinyl, said pyrazinyl and said pyrrolyl groups are optionally substituted with one to three substituents independently selected from the group consisting of hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₈ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ alkylsulfinyl, C₁₋₆ sulfonyl, C₁₋₆ haloalkoxy, C₁₋₆ haloalkylthio, hydroxy, halogen, amino, alkylamino, dialkylamino, aminoacyl, acyl, alkoxycarbonyl, carbamoyl, N-alkylcarbamoyl, N,N-dialkylcarbamoyl, nitro and cyano;

R⁶ is hydrogen, C₁₋₆ alkyl, or acyl;

#143993 v3 10 R0169B-REG

R⁷ and R⁸ taken independently are selected from the group consisting of hydrogen amino, C₁₋₆ alkylamino, C₁₋₆ dialkylamino, amino-C₁₋₃ alkyl, C₁₋₃ alkylamino-C₁₋₃ alkyl, C₁₋₃ alkylamino-C₁₋₃ alkyl or C₁₋₆ alkyl optionally substituted with one or two substituents independently selected from the group consisting of hydroxy, alkoxy, thiol, alkylthio, C₁₋₆ alkylsulfinyl, C₁₋₆ sulfonyl and halogen, N-morpholinyl; n is an integer from 0 to 2;

or an acid addition salt thereof,

in admixture with at least one pharmaceutically acceptable carrier or diluent sufficient upon administration in a single or multiple dose regimen for treating diseases mediated by human immunodeficieny virus inhibit HTV.

11

PAGE 12/14 * RCVD AT 10/31/2006 12:10:19 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-5/2 * DNIS:2738300 * CSID:650 855 5322 * DURATION (mm-ss):02-34

41-51. (canceled)

#143993 v3

R0169B-REG